Stay updated with breaking news from Fred Saad. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A post-hoc analysis of the phase 3 ARASENS trial demonstrated that the addition of darolutamide to androgen deprivation therapy and docetaxel produced deep and durable prostate-specific antigen responses in patients with metastatic hormone-sensitive prostate cancer.
The addition of olaparib to abiraterone acetate resulted in numerically higher prostate-specific antigen response rates and prolonged time to PSA progression vs abiraterone alone when used in the frontline treatment of patients with metastatic castration-resistant prostate cancer.
Proteins produced by muscles during physical activity could inhibit the development of prostate cancer cells and thus slow the progression of the disease, suggests a study involving a Montreal researcher.
Adding olaparib to first-line abiraterone improved radiographic progression-free survival in metastatic castration-resistant prostate cancer.
Adding olaparib to first-line abiraterone improved radiographic progression-free survival in metastatic castration-resistant prostate cancer.